BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 22001608)

  • 1. Synthesis, characterization and evaluation of bone targeting salmon calcitonin analogs in normal and osteoporotic rats.
    Bhandari KH; Newa M; Chapman J; Doschak MR
    J Control Release; 2012 Feb; 158(1):44-52. PubMed ID: 22001608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of trabecular bone, thyroid C and follicular cells to synthetic salmon calcitonin in middle-aged orchidectomized male rats.
    Filipović B; Šošić-Jurjević B; Ajdžanović V; Živanović J; Ristić N; Trifunović S; Milošević V
    J Anat; 2017 Jun; 230(6):787-795. PubMed ID: 28220476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Controlled Drug Delivery for Treatment of Osteoporosis.
    Asafo-Adjei TA; Chen AJ; Najarzadeh A; Puleo DA
    Curr Osteoporos Rep; 2016 Oct; 14(5):226-38. PubMed ID: 27502334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders.
    Sawamoto K; Álvarez JV; Herreño AM; Otero-Espinar FJ; Couce ML; Alméciga-Díaz CJ; Tomatsu S
    Curr Osteoporos Rep; 2020 Oct; 18(5):515-525. PubMed ID: 32845464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate conjugation enhances the bone-specificity of NELL-1-based systemic therapy for spaceflight-induced bone loss in mice.
    Ha P; Kwak JH; Zhang Y; Shi J; Tran L; Liu TP; Pan HC; Lee S; Kim JK; Chen E; Shirazi-Fard Y; Stodieck LS; Lin A; Zheng Z; Dong SN; Zhang X; Wu BM; Ting K; Soo C
    NPJ Microgravity; 2023 Sep; 9(1):75. PubMed ID: 37723136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate Effects on the In Vivo Bioactive Glass Behavior: Nuclear Magnetic Resonance and Histopathological Studies.
    Mosbahi S; Oudadesse H; Roiland C; Lefeuvre B; Slimani L; Keskes H
    Biomed Res Int; 2019; 2019():2175731. PubMed ID: 31915685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites.
    Shi S; Duan H; Ou X
    Biomed Pharmacother; 2024 Jun; 175():116699. PubMed ID: 38705129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioactivity and circulation time of PEGylated NELL-1 in mice and the potential for osteoporosis therapy.
    Zhang Y; Velasco O; Zhang X; Ting K; Soo C; Wu BM
    Biomaterials; 2014 Aug; 35(24):6614-21. PubMed ID: 24818884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue.
    Andreotti G; Vitale RM; Avidan-Shpalter C; Amodeo P; Gazit E; Motta A
    J Biol Chem; 2011 Jan; 286(4):2707-18. PubMed ID: 21078667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Simplified Method for Determining Blood-to-Plasma Ratios
    Zhang X; Jenkins GJ; Desino KE; Liu J; Larsen M; Stresser DM
    Drug Metab Bioanal Lett; 2023; 16(2):113-120. PubMed ID: 37592774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin inhibits SDCP-induced osteoclast apoptosis and increases its efficacy in a rat model of osteoporosis.
    Kuo YJ; Tsuang FY; Sun JS; Lin CH; Chen CH; Li JY; Huang YC; Chen WY; Yeh CB; Shyu JF
    PLoS One; 2012; 7(7):e40272. PubMed ID: 22792258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing Delivery of Therapeutic Growth Factors for Bone and Cartilage Regeneration.
    Takematsu E; Murphy M; Hou S; Steininger H; Alam A; Ambrosi TH; Chan CKF
    Gels; 2023 May; 9(5):. PubMed ID: 37232969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone-Targeted Delivery of Novokinin as an Alternative Treatment Option for Rheumatoid Arthritis.
    Ranjit A; Khajeh Pour S; Aghazadeh-Habashi A
    Pharmaceutics; 2022 Aug; 14(8):. PubMed ID: 36015308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone-targeted delivery of simvastatin-loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment.
    Xie Y; Liu C; Huang H; Huang J; Deng A; Zou P; Tan X
    Drug Deliv Transl Res; 2018 Oct; 8(5):1090-1102. PubMed ID: 30027372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate conjugation for bone specific drug targeting.
    Farrell KB; Karpeisky A; Thamm DH; Zinnen S
    Bone Rep; 2018 Dec; 9():47-60. PubMed ID: 29992180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembled filomicelles prepared from polylactide-poly(ethylene glycol) diblock copolymers for sustained delivery of cycloprotoberberine derivatives.
    Liu X; Wang Y; Yun P; Shen X; Su F; Chen Y; Li S; Song D
    Saudi Pharm J; 2018 Mar; 26(3):342-348. PubMed ID: 29556125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.
    Yang Y; Aghazadeh-Habashi A; Panahifar A; Wu Y; Bhandari KH; Doschak MR
    Drug Deliv Transl Res; 2017 Aug; 7(4):482-496. PubMed ID: 28721611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Drug Carrier for Sustained Zero-Order Release of Peptide Therapeutics.
    Zhao YN; Xu X; Wen N; Song R; Meng Q; Guan Y; Cheng S; Cao D; Dong Y; Qie J; Liu K; Zhang Y
    Sci Rep; 2017 Jul; 7(1):5524. PubMed ID: 28717204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone-seeking agents for the treatment of bone disorders.
    Cawthray J; Wasan E; Wasan K
    Drug Deliv Transl Res; 2017 Aug; 7(4):466-481. PubMed ID: 28589453
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.